Cassava Sciences has filed a patent for a biomarker panel that can be used to diagnose, stage, treat, and assess the response of a treatment for neurocognitive disorders characterized by tau toxicity, such as Alzheimer’s disease. The biomarker panel includes phosphorylated peptides obtained from the in vitro digestion of a Filamin A protein. GlobalData’s report on Cassava Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Cassava Sciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Cassava Sciences, molecular diagnosis biomarkers was a key innovation area identified from patents. Cassava Sciences's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Biomarker panel for diagnosing and treating neurocognitive disorders

Source: United States Patent and Trademark Office(USPTO). Credit: Cassava Sciences Inc

A recently filed patent (Publication Number: US20230144446A1) describes a biomarker panel for the diagnosis and monitoring of neurological diseases, particularly Alzheimer's disease. The biomarker panel consists of phosphorylated peptides obtained from the in vitro digestion of a protein called Filamin A. The Filamin A protein is either contained within or obtained from a biological fluid or tissue sample taken from a subject suspected of having a neurological disease.

The biomarker panel includes phosphorylated peptides that are specifically phosphorylated at residues corresponding to serine 2152, serine 2143, and serine 2180 of the Filamin A protein. These phosphorylated peptides have specific amino acid sequences, which are identified as SEQ ID NO: 2-12. The biomarker panel can comprise a plurality of phosphorylated fragments of Filamin A, with at least two or more fragments or three or more fragments. Additionally, the biomarker panel can include at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 different phosphorylated fragments of Filamin A.

The patent also describes methods for the diagnosis/prognosis of neurological disorders and monitoring their progression using the biomarker panel. These methods involve obtaining a bodily fluid or tissue sample from a subject, digesting the proteins in the sample using proteases, and detecting and measuring the level of peptides produced from the digestion using mass spectrometry. The peptides used for diagnosis/prognosis or monitoring are obtained from the in vitro digestion of the proteins listed in Tables 1-4, which include Filamin A and other proteins.

In summary, the patent presents a biomarker panel consisting of phosphorylated peptides obtained from the digestion of Filamin A protein for the diagnosis and monitoring of neurological diseases, particularly Alzheimer's disease. The biomarker panel includes specific phosphorylated peptides and can be used to detect and measure the level of these peptides in bodily fluid or tissue samples using mass spectrometry. The patent also describes methods for using the biomarker panel in the diagnosis/prognosis and monitoring of neurological disorders.

To know more about GlobalData’s detailed insights on Cassava Sciences, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies